Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARTRUVO vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery, in combination with doxorubicin.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Olaratumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways identified.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 90% bound to plasma proteins (primarily Ig G, as a monoclonal antibody).
Approximately 20–30% bound to plasma proteins.
Central volume of distribution is approximately 4.1 L (0.058 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
100% (intravenous administration only; not bioavailable orally).
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment required for mild to moderate renal impairment (CLcr 30-89 m L/min). Not studied in severe renal impairment (CLcr <30 m L/min) or end-stage renal disease; use only if benefit outweighs risk.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate or severe (Child-Pugh B or C): not studied; use only if benefit outweighs risk.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established in pediatric patients; no recommended dose.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No dose adjustment based on age; monitor for adverse reactions more frequently due to higher incidence of underlying renal or hepatic impairment and comorbidities.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: INFUSION-RELATED REACTIONS (IRRs), INCLUDING DEATH. Serious and sometimes fatal infusion-related reactions can occur. Premedicate and monitor during infusion. Interrupt or permanently discontinue based on severity.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Infusion-related reactions (including severe and fatal); embryo-fetal toxicity; neutropenia; cardiotoxicity (left ventricular dysfunction); and increased adverse reactions in patients with baseline left ventricular ejection fraction (LVEF) below normal.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
None known.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions known. However, doxorubicin may cause nausea and vomiting; advise taking antiemetics as prescribed and eating small, frequent meals. Avoid grapefruit and grapefruit juice as they may affect CYP3A4 metabolism of doxorubicin.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no adequate human data. In animal reproduction studies, administration of olaratumab to pregnant monkeys during organogenesis resulted in embryofetal toxicity including increased abortion and fetal anomalies. Use is contraindicated in pregnancy; advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Risks apply throughout all trimesters.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No data on the presence of olaratumab in human milk, effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
LARTRUVO is contraindicated in pregnancy. No dose adjustments during pregnancy have been studied. Pharmacokinetics may alter due to pregnancy-induced changes in volume of distribution, protein binding, and clearance; however, no specific dose adjustment guidelines exist. If treatment is absolutely necessary in a pregnant patient (which is not recommended), consider therapeutic drug monitoring if feasible.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
LARTRUVO (olaratumab) is a PDGFRα inhibitor used in combination with doxorubicin for advanced soft tissue sarcoma not amenable to surgery or radiotherapy. Monitor for infusion-related reactions and pre-medicate with antihistamines and corticosteroids. Assess cardiac function via echocardiogram or MUGA scan before each cycle due to doxorubicin cardiotoxicity. Neutropenia is common; monitor CBCs before each cycle and hold for ANC <1000/mm3. Olaratumab does not require dose adjustment for mild to moderate hepatic impairment but avoid in severe impairment. No dose adjustment for renal impairment. Pregnancy category D: advise effective contraception during and for 3 months after treatment.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
This medication is given as an intravenous infusion over 60 minutes on Day 1 and Day 8 of each 21-day cycle.,You will receive it together with another chemotherapy drug called doxorubicin.,Common side effects include nausea, fatigue, low white blood cell counts, and infusion-related reactions (fever, chills, shortness of breath).,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising immediately.,Avoid pregnancy and breastfeeding while on this treatment; use effective birth control during and for 3 months after the last dose.,Do not take any other medications, supplements, or herbal products without consulting your doctor.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARTRUVO vs CLADRIBINE, answered by our medical review team.
LARTRUVO is a Antineoplastic Agent that works by Olaratumab is a recombinant human Ig G1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARTRUVO and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARTRUVO is: 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARTRUVO and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARTRUVO is classified as Category C. Based on its mechanism of action (PDGFR-alpha inhibitor) and animal studies, LARTRUVO (olaratumab) is expected to cause fetal harm when administered to pregnant women. There are no. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.